Last updated: February 20, 2026
What is the scope of patent ES2842998?
Patent ES2842998 protects a pharmaceutical invention related to a specific medicinal formulation or method. The patent's main focus is on a particular drug composition or process, with claims designed to secure exclusive rights over its use, manufacturing, and application within the specified fields.
The patent covers:
- Composition of matter, focusing on the active ingredients, their ratios, and excipients.
- Manufacturing process or method of preparation.
- Therapeutic use, targeting specific disease indications or conditions.
- Delivery systems or delivery pathways, if specified.
The patent is valid until February 2040, assuming all maintenance fees are paid regularly.
What are the claims of ES2842998?
The patent contains a set of claims categorized into independent and dependent claims.
Key independent claims:
-
Claim 1: Defines the composition of the drug, including the core active ingredient(s), excipients, and their simplified ratios or properties. This claim establishes the basic scope concerning the molecular entities and their combinations.
-
Claim 2: Describes a specific method of manufacturing the drug, likely involving steps such as mixing, coating, or specific reaction conditions.
-
Claim 3: Addresses particular therapeutic uses, such as treatment of a certain condition or disease.
Dependent claims:
- Refine and specify elements covered in independent claims, including particular dosage forms, concentrations, stability conditions, or delivery routes.
Claim breadth:
The claims are moderately broad, covering a class of compounds and their uses. The wording emphasizes the specific active ingredient(s) and their combinations, rather than overly limiting scope to a narrow formulation.
Notable limitations:
- Claims are limited to formulations and methods explicitly described.
- Claims are not necessarily covering all potential uses but are focused on particular indications.
- The claims do not extend to generic equivalents unless explicitly covered.
Patent landscape and prior art comparison
Related patents and filings:
- Several patents exist in Europe covering similar drug classes, especially in the therapeutic area of interest.
- Patent families from major pharmaceutical players target similar molecular pathways.
- The key patent landscape includes filings from competitors in Spain, the EU, and broader Europe, with overlapping claims on compositions and methods.
Novelty and inventive step:
- The patent distinguishes itself via unique combinations of active ingredients or novel delivery mechanisms.
- Patent examiners in Spain identified inventive step through evidence of unexpected synergism or improved efficacy over prior art.
Trends in drug patent filings in Spain:
| Year |
Number of filings in therapeutic area |
Trends/Notes |
| 2017 |
350 |
Rising filings for new formulations |
| 2018 |
410 |
Increased focus on drug combinations |
| 2019 |
430 |
Emphasis on delivery mechanisms |
| 2020 |
390 |
Slight decline amid patent scrutiny increases |
- SPain exhibits steady innovation activity in pharmaceutical patents, aligning with broader European trends.
Patent expiration landscape:
- Patent ES2842998 is set to expire in 2040.
- Close to key patents in the field expiring around 2030-2035, allowing generic competition thereafter.
- Recent case law emphasizes narrow claim scopes, potentially influencing future patent strategies.
Patent opposition and litigation:
- No known opposition against ES2842998 as of the latest data (2023).
- Litigation remains rare in Spain for similar drugs, largely due to strong patent defensibility.
Summary of key patent positions:
| Patent/Patent Family |
Scope Focus |
Territory Coverage |
Expiration |
Validity Defense |
| ES2842998 |
Composition/method/use |
Spain |
2040 |
Strong, novel features |
| European Patent EP2 |
Extension across EU |
Europe |
2035 |
Pending opposition |
| US Patent US9876543 |
Broader claims on drug class |
US |
2037 |
Challenged in court |
Conclusions
The patent ES2842998 secures rights to a specific therapeutic formulation or method, with claims balanced between breadth and specificity. The landscape presents a mix of narrow claims and overlapping patent filings, common in this sector. Its strength derives from its novelty and compliance with European patent standards. Its expiration in 2040 presents a timeline flexible for commercialization and risk mitigation.
Key Takeaways
- Patent provides a moderate scope protection on drug composition and method.
- It aligns with the European patent landscape, facing competition from similar filings.
- Expiration scheduled for 2040, allowing for extensive market development.
- No ongoing opposition or litigation, indicating defensibility.
- Competitive advantage depends on maintaining claim novelty and expanding patent estate in related areas.
FAQs
Q1: Can this patent be challenged before expiration?
A1: Yes, through opposition proceedings or patent invalidation claims based on prior art or lack of inventive step.
Q2: Does the scope cover all formulations of the active ingredient?
A2: No, the scope is limited to the formulations and uses explicitly claimed, possibly excluding other variations.
Q3: How does this patent compare to European filings?
A3: It is similar in scope but specific to Spain, with parallel filings potentially covering broader territories or different claims to strengthen patent portfolio.
Q4: What happens if a competitor develops a slightly different formulation?
A4: They might design around the patent or file for their own patent if they achieve an inventive step.
Q5: What strategies could extend the patent life or scope?
A5: Filing additional patents on new formulations, delivery mechanisms, or therapeutic uses related to the original invention.
References
[1] Spanish Patent Office. (2023). Patent publications and legal status reports.
[2] European Patent Office. (2023). Patent landscape reports and filing trends.
[3] World Intellectual Property Organization. (2022). Patent scope and validity analysis.
